Vimarsana
Biggest News Aggregation in the World

Technical Resources Intl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Technical Resources Intl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Technical Resources Intl Today - Breaking & Trending Today

Biden admin seeks additional funding for new COVID vaccine 'that works' - Vimarsana News

Biden admin seeks additional funding for new COVID vaccine 'that works'

By Jim Hᴏft The Gateway Pundit The Gateway Pundit previously reported that InfoWars published insider information that alleges the TSA and US Border Patrol will be moving back to 2020-era COVID-19 mandates and restrictions starting in mid-September through mid-October, to include mask mandates on all flights. This is in addition to the confirmed mask-mandate reinstatement…

Source: wnd.com
2:00PM Water Cooler 8/23/2023 | naked capitalism - Vimarsana News

2:00PM Water Cooler 8/23/2023 | naked capitalism

Today's Water Cooler

HHS Makes $1.4B Investment in COVID-19 Vaccine Development, Clinical Trials - Vimarsana News

HHS Makes $1.4B Investment in COVID-19 Vaccine Development, Clinical Trials

Looking for the latest GovCon News? Check out our story: HHS Makes $1.4B Investment in COVID-19 Vaccine Development, Clinical Trials. Click to read more!

Project NextGen awards over $1.4 billion to develop the future of COVID-19 vaccines and therapeutics - Vimarsana News

Project NextGen awards over $1.4 billion to develop the future of COVID-19 vaccines and therapeutics

Funding includes $1 billion for vaccine clinical trials, $326 million for a new monoclonal antibody, and $100 million to explore novel vaccine and therapeutic technologies.

$1B for new COVID vaccines, $300M for new antibody to protect vulnerable - Vimarsana News

$1B for new COVID vaccines, $300M for new antibody to protect vulnerable

The money will be split by small biotech companies that might struggle to pay for clinical trials comparing new vaccines against those now available.